Peregrine Pharmaceuticals (PPHM ) announced today that it discovered major discrepancies between some patient sample test results and patient treatment code assignments during the course of preparing for an end-of-phase II meeting with regulatory authorities. Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according […]
By Mr. BiotechIll, Guest Author Shares of Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) gain almost half their value after announcement that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). At glance: Data show statistically significant improvement in overall survival for patients receiving […]
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today 20.7 month median overall survival results based on Phase II study of bavituximab in combination with docetaxel in patients with metastatic breast cancer. PPHM has been traded 3 fold of its 10day average volume as of 10:15 a.m. EST Peregrine Pharmaceuticals Inc. 14282 Franklin Avenue Tustin, CA 92780 United […]
